Objective: To evaluate the additive value of the prostate cancer gene 3 (PCA3) urine test to serum prostate-specific antigen (PSA) in prostate cancer (PC) screening among breast cancer, early-onset gene (BRCA) mutation carriers. This study was performed among the Dutch participants of IMPACT, a large international study on the effectiveness of PSA screening among BRCA mutation carriers.
Introduction
Prostate cancer (PC) is the most frequently diagnosed cancer in men in the Western world [1] . Serum prostatespecific antigen (PSA) testing is the only commonly used biomarker for PC, but its low specificity has led to a consensus not to implement population-wide screening [2, 3] . Possibly, the advantages of screening may outweigh the disadvantages for groups with an increased risk of PC. It has been suggested that carriers of a pathogenic mutation in one of the "breast cancer, early-onset" genes (BRCA1 or BRCA2) have an increased risk of PC [4, 5] . Particularly, BRCA2 mutation carriers might present with PC at a younger age, more aggressive disease, and shorter survival [6] [7] [8] [9] [10] . To evaluate the effectiveness of PSA screening in BRCA mutation carriers, an international study was initiated, entitled "IMPACT: Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls" (www.impact-study.co.uk). The results of IMPACT's first screening round have already been published. These preliminary results support PSA screening among BRCA2 mutation carriers [11, 12] .
The large number of false-positive results on PSA tests, particularly in the range of 3 to 10 ng/ml, has prompted ongoing research into new (bio)markers to improve PC diagnosis. One of the promising biomarkers, prostate cancer gene 3 (PCA3), was discovered in 1999 as a gene that is strongly up-regulated in PC [13] . Based on the prostatespecific and cancer-associated expression of PCA3, the PROGENSA urine-based test was developed. Previous multicenter studies suggested that its specificity and sensitivity were significantly higher than those of evaluation of serum PSA levels [14] [15] [16] . PCA3 is currently used as a biomarker to determine the need for repeat biopsies when PSA level remains elevated after prostate biopsies with negative results. We aimed to determine the potential role of PCA3 in addition to PSA testing in this high-risk group by performing a substudy among the Dutch participants of IMPACT.
Materials and methods
Men who were eligible for IMPACT, i.e., BRCA mutation carriers and their relatives who were proven noncarriers, were identified and contacted by the 10 Dutch Clinical Genetic Centres. All eligible men received an invitation by mail, including a detailed patient information leaflet describing IMPACT and the Dutch substudy (IMPACT-NL). The IMPACT protocol has been described in detail elsewhere [17] . Owing to restrictions set by the Dutch Minister of Health (the Dutch "Law on Screening" requires all cancer screening projects to obtain ministerial approval), the IMPACT-NL protocol ( Fig. 1 ) deviated from the IMPACT protocol: (1) the screening interval was once every 2 years instead of annually; (2) men were eligible if they were between 45 and 69 years instead of 40 to 69 years of age; (3) only men who were not tested for PC before were eligible; and (4) end-of-study biopsies were not allowed. Informed consent was sent to the study coordinator (J.R.B.) at the Netherlands Foundation for the Detection of Hereditary Tumours.
Of the 2,181 men who were invited, 500 refused consent and 458 did not reply. Of the 1,223 men providing informed consent, 552 had undergone previous PC testing (including 42 men with PC) and were excluded (Fig. 2) . Of the 671 remaining men, 634 completed a baseline questionnaire and were referred to a urologist. In IMPACT-NL, in addition to a serum sample for PSA analysis (analyzed at the screening site) all participants provided a urine sample after digital rectal examination (DRE). The urine samples were collected by the urologist at the screening site, immediately transferred to collection and transportation tubes, and sent to NovioGendix Servicelab (Nijmegen, the Netherlands). On arrival, the samples were frozen and stored. Samples were analyzed according to the manufacturer's protocol in regular runs together with clinical samples, using the PROGENSA PCA3 test. The initial screening round was completed by 574 participants (191 BRCA1 mutation carriers, 75 BRCA2 mutation carriers, and 309 noncarriers). To avoid interference with the IMPACT protocol, PCA3 scores were not used to indicate prostate biopsies. To ensure this, both urologists and participants were blinded toward the PCA3 scores.
Prostate biopsies were taken at the departments of urology of the hospitals of referral, all of which adhere to the guidelines of the Dutch Association of Urology. According to this guideline, at least 8 transrectal prostate biopsies are taken (the traditional "sextant biopsies" complemented with at least one extra biopsy on each side-preferably from the anterolateral peripheral zone). If PC was diagnosed, staging and treatment decisions were based on to the national guidelines at the discretion of the treating urologist.
If participants had an elevated PSA level and negative results on prostate biopsy, they were rescreened after 1 year (repeat screening round). Men with a normal PSA level on the initial screening were rescreened after 2 years. The results of the repeat and the 2-year screening round were also presented, as to enable the detection of PC up to and until the second screening (a 2-y period) to serve as gold standard for the diagnostic performance in the initial screening round.
The [18, 19] . If postsurgical TNM staging and Gleason score were not available, clinical stage and biopsy Gleason score were used. Data regarding carrier status and the PCA3 scores were sent directly to the study coordinator (J.R.B.), who coded and stored all data. The first author (R.C.) was provided with an anonymized version of the database to perform the data analyses.
Statistical analysis
PCA3 was evaluated (1) as a supplementary test, indicating prostate biopsies if either PSA level or PCA3 was increased or Fig. 2 . Flowchart of the invitations and response rates for the Dutch part of the IMPACT study.
(2) as a restrictive test, indicating prostate biopsies only if PCA3 was elevated among men with an elevated PSA levels. Cutoff values Z25 and Z35 for PCA3 were evaluated and results were stratified by BRCA mutation status. We calculated detection rates as a percentage of diagnoses for all participants per BRCA mutation stratum and the positive predictive value (PPV) of the PSA test among the biopsied men per stratum. We calculated the Spearman rho correlation between PCA3 and PSA level and made cross-tables for the concordance between PCA3 and PSA level.
Results
The BRCA mutation carriers and the noncarriers were comparable with respect to age, BMI, and comorbidity. The BRCA2 mutation carriers more often reported a medical history of neoplasms (Table 1) , particularly nonmelanoma skin cancer (5 noncarriers, 2 BRCA1, and 2 BRCA2 mutation carriers), colorectal cancer (2 noncarriers, 4 BRCA1, and 2 BRCA2 mutation carriers) and breast cancer (1 noncarrier and 4 BRCA2 mutation carriers).
In the initial screening round, PSA was elevated in 75 participants (Table 2 ). Additionally, 6 of these men also had abnormalities on DRE. Of the participants with an elevated PSA level, 69 underwent prostate biopsies, including all 6 men with abnormalities on DRE. In 14 of these men, PC was diagnosed (PPV 14/69 ¼ 20%), none of whom had abnormalities on DRE. Of the men with a normal PSA level, 7 had abnormalities on DRE, 4 of whom underwent prostate biopsies. Additionally, 4 men with a normal PSA level and a normal findings on DRE underwent prostate biopsies. No PCs were found among these men. The detection rate in BRCA2 mutation carriers was 4.0% vs. 1.6% in BRCA1 carriers and 2.6% in noncarriers.
In the repeat screening round among 52 men with an elevated PSA level and negative findings on biopsies, 5 PCs were diagnosed.
In the 2-year screening round, 50 men had an elevated PSA level, including 4 with abnormalities on DRE. Of the, 25 men underwent prostate biopsies. Further, 4 PCs were detected in 435 screened men (78% of the 556 men at risk). One of these 4 men also had abnormalities on DRE in this round and 3 had PSA levelo3.0 ng/ml in the initial screening round. In the initial screening round, PSA level was elevated for all 13 intermediate-and high-risk PCs detected in this study (Table 3) , 11 of which were detected in the first biopsy session. PSA performed best among BRCA2 mutation carriers, i.e., in this group, all PCs were detected in the initial screening round. Using the gold standard of PC detected in the first 2 years, the diagnostic performance of PSA among BRCA2 carriers was as follows: PPV ¼ 25%, sensitivity ¼ 100%, negative predictive value (NPV) ¼ 100%, and specificity ¼ 85%. DRE showed very poor results, with abnormalities in only 2 (1 low-risk and 1 intermediate-risk PC) of the 23 PCs.
The PCA3 score was successfully determined in 552 men (96%). The correlation between PSA level and PCA3 was 0.19 ( Fig. 3) . Use of PCA3 Z 25 as a supplementary marker would result in 157 additional biopsies, more than double the number of biopsies indicated by PSA alone (Table 4) . Among these 157 men (28%), 2 men were diagnosed with PC during the 2-year screening round, based on an increased PSA level. A PCA3 score Z35 would indicate prostate biopsies for 109 (20%) additional men, including the same 2 men with PC diagnosed after 2 years. The results for PCA3 Z 35 were best for the BRCA2 mutation carriers (PPV ¼ 13% in the absence of biopsies indicated by high PCA3; NPV ¼ 98%), although the absolute numbers were small. Use of PCA3 to withhold biopsies in men with an elevated PSA level would have reduced the number of biopsies in the initial screening round by more than half from 68 to 31 (Table 4) . A PCA3 cutoff Z35 would have decreased this further to 25 biopsy sessions. This would come at the cost of missing, respectively, 7 and 11 PCs of the 22 PCs in this substudy. Among these, multiple intermediate-and high-risk PCs would have been present.
Discussion
This study did not find a clear role for PCA3 in addition to PSA screening among BRCA mutation carriers. Use of PCA3 as a supplementary indicator of prostate biopsies seemed to result in a relatively large number of additional prostate biopsies to identify only a few PCs. However, in the absence of end-of-study biopsies, it is impossible to estimate the real PPV of PCA3 at this point. We can conclude that a restrictive use of PCA3, i.e., to diminish the number of biopsies among men with an elevated PSA level, is not a good strategy in this study population. Too many intermediate-and high-risk PCs would be missed, if prostate biopsies were to be withheld based on the PCA3 score.
PSA level in the initial screening round showed good results, appearing to miss only 3 PCs that were detected in the 2-year follow-up (FU), although not all PCs were found in the first biopsy session. All PCs that were detected during the 2-year screening round were low-risk PCs that revealed themselves by an increased PSA level during the 2-year screening round. These results might be an overestimation, as no end-of-study biopsies were performed. One may argue that end-of-study biopsies would give a more reliable estimate of the NPV of PSA than our somewhat arbitrary gold standard of PC detected in the first 2 years in this study. The counter argument is that end-of-study biopsies lead to a considerable overdiagnosis of PC, as was shown in the PCPT trial [20] . A better alternative for end-of-study biopsies is a much longer FU period to see which men will be diagnosed with PC. Another comment to the current screening strategy could be that, even though it does not seem likely that many high-risk PCs were missed, the BRCA2 mutation carriers might require an even more stringent PSA cutoff, as discussed by Bancroft et al. [12] . In the absence of end-of-study biopsies or a longer FU period, we can only speculate about whether a different PSA cutoff should be used in BRCA2 mutation carriers. Unfortunately, a limitation of the study is that the financial resources prohibited more screening rounds. For example, for a good evaluation of the risk of interval cancers, complete FU until the third screening round is necessary.
The results for PCA3 seem modest. For comparison purposes, the most important study is by Roobol et al. [21] , which is to our knowledge the only study that used PCA3 (cutoff Z10) as a supplementary indicator for prostate biopsies. Their biopsy protocol (biopsy indicated for either PSA level Z3.0 ng/ml or PCA3 Z 10) resulted in 721 of the 965 men (75%) being biopsied. In these biopsy sessions, 122 PCs were diagnosed, only 19 of which were classified as "serious" PCs (defined as stage ZcT2a or any Gleason a Reported reasons for nonparticipation in the subsequent screening rounds were mainly: personal reasons (n ¼ 19), health insurance issues (n ¼ 28), other illness (n ¼ 11), second-year screening still to be performed (n ¼ 17), and second-year screening results still to be received (n ¼ 20). Only men with PSA level Z3.0 ng/ml underwent prostate biopsies. The 3 PCs in men with an initial PSA level o3.0 ng/ml were detected during the 2-year screening round; these participants underwent prostate biopsies because of a PSA level that had increased to Z3.0 ng/ml in the time between the initial and the 2-year screening round. Of the PCs detected in men with a PSA level Z3.0 ng/ml, 6 were detected in the repeat and second screening rounds after negative biopsy results in the previous screening round.
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In our substudy, the BRCA2 mutation carriers had an increased prevalence of PC in the first screening round. This difference diminished, as PCs in the consecutive screening rounds were only detected among BRCA1 mutation carriers and noncarriers. The suggested association between BRCA mutations, particularly BRCA2 mutations, and PC risk is more supported by the number of PCs detected before the study (Table 3 ). This may be the reflection of the genetically increased risk of PC that men with a BRCA mutation have been reported to have. An alternative explanation is ascertainment bias. It is imaginable that particularly men with a known BRCA mutation were more intensively screened for PC before IMPACT than noncarriers, as a relationship between BRCA mutations and PC has been reported for quite some time. Either way, assuming that a causal relationship exists between a germline BRCA mutation and PC, the exclusion of these family members from this study cannot affect the results among screening-naïve participants [24] . The highest PPV for PSA level was found for BRCA2 mutation carriers, suggesting that this might be the most interesting group for further research. PCA3 also performed best among BRCA2 mutation carriers. However, the absolute numbers (3 PCs were detected among 75 BRCA2 mutation carriers) are small, warranting caution when drawing any conclusions.
Conclusions
PCA3 should not be used as a restrictive marker next to PSA level for PC screening in BRCA mutation carriers. PCA3 did not show sufficient additive value to be implemented as a supplementary indicator of prostate biopsies next to PSA level, although in the absence of prostate biopsies based on PCA3, its true diagnostic performance cannot be calculated. A longer FU period is needed to show whether PCA3 will be a valuable addition to any PC screening protocol.
